Chimeric Therapeutics Limited is an Australia-based clinical-stage cell therapy company. The Company is focused on the discovery, development, and commercialization of cell therapies for patients with cancer. Its pipeline includes CHM 1101 and CHM 2101. Its CHM 1101 (CLTX CAR-T) is a CAR-T therapy developed for the treatment of patients with solid tumors. CHM-1101 is being studied in a Phase 1B clinical trial in recurrent/ progressive glioblastoma. CHM 2101 is a third generation CDH17 CAR T, which is in preclinical development with a planned Phase I clinical trial in neuroendocrine tumors, colorectal, pancreatic and gastric cancer. Its pipeline also includes the CORE-NK platform, a clinically validated, off-the-shelf natural killer (NK) cell therapy platform to their portfolio (CHM 0201). The Company is also focused on the development of NK and CAR NK assets with plans for Phase 1B clinical trials in solid tumors and blood cancers.

• Revenue in AUD (TTM)0.00
• Net income in AUD-12.53m
• Incorporated2020
• Employees--

• Location
  Chimeric Therapeutics LtdLevel 3, 62 Lygon Street, CarltonMELBOURNE 3053AustraliaAUS
• Phone+61 39824-5254
• Fax+61 39822-7735
• Websitehttps://chimerictherapeutics.com/